ClinicalTrials.gg
CompletedNCT07252921Updated Jan 29, 2026

Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults

A Phase 2 interventional study of HRS-9190 and HRS-9190 in Neuromuscular Blockade, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study will enroll adult patients scheduled for elective surgery requiring general anesthesia with tracheal intubation. Participants will be randomly assigned to receive either HRS-9190 for Injection or Rocuronium. The primary objective is to assess the efficacy of HRS-9190 in providing adequate neuromuscular blockade for successful tracheal intubation. Secondary objectives include evaluating the onset time, duration of action, and recovery profile of neuromuscular blockade. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation for tracheal intubation, with a satisfied safety profile in the target patient population.

02

Conditions studied

  • Neuromuscular Blockade
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Subjects requiring elective general anesthesia surgery
  3. Meet specified age and (BMI) criteria
  4. Conform to the ASA Physical Status Classification
  5. Use of highly effective for a specified period if applicable

Exclusion criteria

Exclusion Criteria:

  1. Scheduled for specific high-risk surgical procedures
  2. History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
  3. History of conditions affecting drug metabolism or anesthesia risk
  4. Abnormal laboratory values indicating significant clinical abnormalities
  5. Positive serology for specified infectious diseases
  6. Known to related medications
  7. Recent use of medications interfering with neuromuscular function
  8. History of mental illness, cognitive impairment, or epilepsy
  9. Participation in another clinical trial within a specified period
  10. Any other condition deemed unsuitable by the investigator
  11. Pregnant or nursing women
  12. Unwilling to use during the specified period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Treatment group A: HRS-9190

    Drug: HRS-9190

  • Experimental
    Treatment group B: HRS-9190

    Drug: HRS-9190

  • Active comparator
    Treatment group C: Rocuronium Bromide Injection.

    Drug: HRS-9190

Interventions

06

What researchers measure

Primary outcomes

  1. Intubation conditions

    Proportion of subjects with excellent or good intubation conditions as assessed by the Cooper score

    Time frame: Within 5 minutes after administration of the study drug

Secondary outcomes

  1. Time to Maximum Inhibition (Onset Time)

    The time from the start of injection of the study drug to the time when T1 reaches 0% of its baseline value, indicating complete neuromuscular blockade and maximum drug effect.

    Time frame: From start of study drug administration until the time when T1 reaches 0% (maximum suppression), Estimated within 5 minutes

  2. Time to Successful Tracheal Intubation

    The time from the start of injection of the study drug to the time when the endotracheal tube is correctly placed and secured, as confirmed by the anesthesiologist.

    Time frame: From start of study drug administration to the completion of tracheal intubation, Estimated within 5 minutes

  3. Time to Recovery of T1 to 10%/25% of Baseline

    The duration of action measured as the time from injection to the time when the first twitch (T1) recovers to 10%/25% of its pre-drug baseline height.

    Time frame: From start of study drug administration until the time when T1 recovers to 10% /25% of its baseline value, Estimated within 30 minutes

  4. Time to Recovery of Train-of-Four Ratio (TOFr) to 0.4/0.7/0.9

    The time from injection to recovery of the ratio of the fourth twitch (T4) to the first twitch (T1) to 0.4, which is a marker of adequate recovery for spontaneous ventilation.

    Time frame: From start of study drug administration until the time when the TOFr recovers to 0.4/0.7/0.9, Estimated from 15 to 90 minutes

  5. Recovery Index (T1 25% to 75% and T1 5% to 95%)

    Time frame: within 2 hours after administration of research drug

07

Study locations

2 sites
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 28, 2025
StartActual
Oct 30, 2025
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07252921
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Oct 30, 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Jan 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9190

Start the discussion